Touro University Nevada, Henderson, Nevada.
Ann Intern Med. 2021 Jun;174(6):ITC81-ITC96. doi: 10.7326/AITC202106150. Epub 2021 Jun 8.
Many groundbreaking advances have occurred in the field of multiple sclerosis since this series last reviewed the disorder in 2014. The U.S. Food and Drug Administration has approved 7 new medications for relapsing-remitting multiple sclerosis and approved the first medication for primary progressive multiple sclerosis. The McDonald criteria for diagnosing multiple sclerosis were updated in 2017. New blood tests can now differentiate patients with multiple sclerosis from those with neuromyelitis optica spectrum disorder, and 3 new medications have been approved specifically for the latter disorder. Also, new medications for treating the symptoms of multiple sclerosis have been introduced.
自 2014 年本系列文章上次综述多发性硬化症以来，该领域取得了许多突破性进展。美国食品和药物管理局已批准 7 种新的多发性硬化症缓解期治疗药物，并批准了第一种原发性进展性多发性硬化症治疗药物。2017 年，多发性硬化症的麦当劳诊断标准进行了更新。现在，新的血液检测可将多发性硬化症患者与视神经脊髓炎谱系疾病患者区分开来，并且已批准 3 种新的药物专门用于治疗后者疾病。此外，还推出了治疗多发性硬化症症状的新药物。
